Vertaling van "marketable securities as these " (Nederlands → Frans) :

Current assets decreased by USD 6.0 billion mainly due to USD 9.5 billion lower cash and marketable securities as these funds were used to acquire the additional 52% of Alcon.
Les actifs courants ont baissé d’USD 6,0 milliards, en raison essentiellement d’une diminution du numéraire et des titres de placement négociables, car ces fonds ont été utilisés pour acquérir la participation additionnelle de 52% dans Alcon.

These outflows were partially offset by USD 3.3 billion in net proceeds from the sale of marketable securities.
Ces sorties ont été en partie compensées par un montant d’USD 3,3 milliards de produits nets provenant de la vente de titres de placement négociables.

Although cash and marketable securities rose by USD 2.4 billion as a result of reinvesting proceeds from the US dollar bond issued in March 2010, these were nearly offset by reductions due to currency changes (USD 2.0 billion) and lower underlying trade receivables (USD 0.3 billion).
La trésorerie et les titres de placement négociables ont progressé d’USD 2,4 milliards à la suite du réinvestissement du produit de l’émission, en mars 2010, d’un emprunt obligataire libellé en dollars. Ce montant a été presque entièrement compensé par des réductions dues à l’évolution des taux de change (USD 2,0 milliards) et à une diminution sous-jacente des comptes clients (USD 0,3 milliard).

These outflows were partially compensated by the net inflow from the sale of marketable securities of USD 12.8 billion.
Ces sorties de trésorerie ont été en partie compensées par des entrées nettes d’USD 12,8 milliards provenant de la vente de titres de placement négociables.

Balance sheet Total assets increased to USD 90.7 billion at the end of the 2009 third quarter compared to USD 78.3 billion at the end of 2008 mainly as a result of proceeds from recent bond issues, which are held as cash and marketable securities, and intangible assets acquired through the September 2009 purchase of EBEWE Pharma’s specialty generics business.
Bilan Le total de l’actif a augmenté à USD 90,7 milliards à la fin du troisième trimestre 2009, par rapport à USD 78,3 milliards à fin 2008, résultant principalement du produit des récentes émissions d’obligations, qui est détenu en espèces et en titres de placement négociables, et des immobilisations incorporelles acquises lors de l’achat, en septembre 2009, du domaine thérapeutique des spécialités génériques d’EBEWE Pharma.

Cash outflows from investing activities reached USD 10.0 billion in the first nine months of 2009 and included USD 7.5 billion in marketable securities investments with proceeds from bond offerings as well as USD 0.9 billion related to the EBEWE Pharma generics business acquisition and USD 1.3 billion for capital expenditures.
Les sorties de trésorerie liées aux activités d’investissement se sont élevées à USD 10,0 milliards durant les neuf premiers mois de 2009. Elles ont compris USD 7,5 milliards de titres de placement négociables achetés avec les produits des émissions obligataires ainsi qu’un montant d’USD 0,9 milliard relatif à l’acquisition du secteur des génériques d’EBEWE Pharma et USD 1,3 milliard en immobilisations corporelles.

USD m USD m USD m Change in cash and cash equivalents 735 –911 1 646 Change in marketable securities, financial debt and financial derivatives 312 –9 163 9 475
M USD M USD M USD Variation de la trésorerie et des équivalents de trésorerie 735 –911 1 646

The cases dealt with in these meetings may be complaints by consumers or producers, requests for advice from inspection services, formal opinions on the formulation of regulations, formal opinions for companies wishing to market products and to ensure that they are presenting their product correctly, and internal cases that serve for the compilation of guidelines for the consultation platform.
The cases dealt with in these meetings may be complaints by consumers or producers, requests for advice from inspection services, formal opinions on the formulation of regulations, formal opinions for companies wishing to market products and to ensure that they are presenting their product correctly, and internal cases that serve for the compilation of guidelines for the consultation platform.

However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.
However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.

On the basis of these European directives, the FAMHP is thus mainly responsible for supervision of the market by following up on incidents (materiovigilance) and by inspecting manufacturers, distributors and retailers established in Belgian territory.
On the basis of these European directives, the FAMHP is thus mainly responsible for supervision of the market by following up on incidents (materiovigilance) and by inspecting manufacturers, distributors and retailers established in Belgian territory.